USE OF PHTHALIMIDE AND/OR SULPHONAMIDE DERIVATIVES IN THE TREATMENT OF DISEASES WHICH REQUIRE REDUCING THE TNF-alpha LEVELS AND AN EXOGENOUS SOURCE OF NITRIC OXIDE, PHTHALIMIDE DERIVATIVES, SULPHONAMIDE DERIVATIVES, AND A METHOD FOR OBTAINING A SULPHONAMIDE DERIVATIVE

Abstract

The present invention refers to the use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, which have important activities in increasing the gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-α levels and an exogenous source of nitric oxide. More particularly, the present invention describes the use of such phthalimide and/or sulphonamide derivatives for the treatment of sickle-cell disease. The invention also has as a novel characteristic the disclosure of new functionalized phthalimide derivatives designed from the prototypes thalidomide and hydroxyurea, and designed rationally through the strategy of molecular hybridization for the treatment of said diseases. The invention still discloses a new method for obtaining a specific sulphonamide derivative which can be used in the preparation of a drug for the treatment of diseases which require reducing the levels of the TNF-α factor and an exogenous source of nitric oxide.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to view more

AI Technical Summary

Benefits of technology

The invention proposes new treatments for sickle-cell disease that can improve patients' lives by reducing the side effects and difficulties often encountered when taking traditional drugs. These improvements are achieved through the use of nitric oxide donors and special molecules called phthalimide and sulfonamide derivatives which help regulate the production of tumour necrosis factor (TNF)- α.

Problems solved by technology

The patent text discusses the problem of high TNF-α levels and the negative effects of commonly-used compounds, such as hydroxyurea and infliximab, on patients with sickle-cell disease. The invention aims to provide a new alternative for the reduction of TNF-α levels and the need for an exogenous source of nitric oxide. The text also describes the use of new phthalimide and sulphonamide derivatives in the preparation of drugs for the treatment of diseases involving the reduction of TNF-α levels. The invention provides new phthalimide and sulphonamide derivatives for the treatment of sickle-cell disease.

Images